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Blood samples submitted to the Immunology Laboratory at
the William R. Pritchard Veterinary Medical Teaching Hospital,
University of California at Davis from 12/1/2009 to 11/30/2011
for the detection of specific antibodies to Sarcocystis neurona and
N. hughesi were reviewed. The samples were accompanied by a
submission form which contained information regarding the ori-
gin, signalment and neurological signs of the suspected EPM
cases. Case selection included horses with neurological deficits,
which tested seropositive by the NeoFluor indirect fluorescent
antibody test to N. hughesi (titer  320). Concurrent titers to S.
neurona were also evaluated.
Over the 24-month study period 7,250 submissions of sus-
pected EPM cases were processed for antibody detection to N.
hughesi and S. neurona. One-hundred and fifteen samples tested
seropositive for N. hughesi with titers ranging from 320 to 10,240
(median 640). 54/115 (47%) N. hughesi seropositive horses also
had antibody against S. neurona with titer ranging from 80 to
5,120 (median 320). In 34 dually seropositive serum samples,
titers to N. hughesi were higher than titers to S. neurona. Seven
serum samples had similar titers for N. hughesi and S. neurona
and 13 serum samples had higher titers to S. neurona than to N.
hughesi. The number of N. hughesi seropositive horses ranged
from 1 to 12 per month and they originated from 29 different
States (TX 24 index cases; CA 18; OK 8; NY/VA 7; FL/PA/MO
5; GA/NJ 4; TN/IL/WA/NC/CT/AL/AR/ID/MT 2; MA/AZ/
MN/OH/SC/IA/NV/NM/WY/WV 1). The age of seropositive
horses ranged from 1 to 33 years (median 10 years) and a variety
of breeds were represented including quarter horse, thorough-
bred, warmblood, Arabian, draft breeds and other breeds. Most
commonly reported clinical signs in N. hughesi seropositive index
cases were ataxia (62%), weakness (38%), lameness/gait abnor-
mality (34%) and muscle atrophy (29%).
The results of this retrospective study show that N. hughesi is,
alone or in combination with S. neurona, associated with EPM
cases. The wide geographic origin of N. hughesi seropositive
horses highlights the need to test for both apicomplexan proto-
zoal pathogens in neurologically affected horses with suspected
EPM.
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The effect of catheter material on intravenous catheterisation
complications in horses are unknown. This study evaluated the
presence of bacterial colonisation on Teflon® and polyurethane
short term intravenous catheters in healthy adult horses undergo-
ing elective surgery.
Horses on admission for elective surgery were randomly allo-
cated according to catheter type. Sixteen horses received Teflon®
catheters and 19 received polyurethane. Aseptic catheter place-
ment and removal was standardised, however systemic antibiotic
treatment was case dependant and at the clinician’s discretion.
To simulate routine clinical practice, face masks were not worn
during placement nor were the catheters bandaged. Catheters
were maintained for 74 hours and assessed for clinical evidence
of catheter site reaction, phlebitis or thrombosis twice daily.
Bacteria were cultured from 69% of Teflon® and 89% of
polyurethane catheters. Multiple isolates were found in 31% of
Teflon® and 42% of polyurethane catheters The Fisher exact test
showed no difference between the proportion of catheters with
colonisation (P=0.28) or multiple isolates (P=0.76). The
microbes cultured were predominantly gram positive, similar to
other equine and human studies. Multiple-drug resistance was
seen regularly, regardless of antibiotic treatment. Despite this, no
clinical evidence of phlebitis or thrombosis occurred in any
horse.
It was concluded, that was no clear association between bacte-
rial colonisation of Teflon® or polyurethane catheters
(0.9<RR<1.87). The unexpected large proportion of bacterial
isolates in the absence of clinical signs was also evaluated and
suggests that the equine immune system plays a role in the devel-
opment of septic phlebitis or thrombosis.
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Equine rhinitis viruses (ERV1&2) have been associated with
respiratory disease outbreaks worldwide. ERV 1&2 infections
cause subclinical signs or respiratory signs including fever, nasal
discharge, coughing, anorexia, pharyngitis, laryngitis and
enlarged submandibular lymph nodes. Over the past decade,
serologic evidence of infection has been documented in Canada,
Australia, and Europe. However, recent serologic data does not
exist in US horse populations. The purpose of this study was to
determine seroprevalence of ERV 1&2 in different regions of the
US.
Frozen serum samples were obtained from six US veterinary
laboratories, Animal Health Diagnostic Center (AHDC) at Cor-
nell University SVM, Ithaca, NY, Texas Veterinary Medical
Diagnostic Laboratory Amarillo, TX, Veterinary Diagnostic Lab-
oratory Lexington, KY, University of California at Davis Veteri-
nary Teaching Hospital, Davis CA, Louisiana Animal Disease
Diagnostic Laboratory, Equine Health Studies program, Baton
Rouge, LA, and Equine Diagnostic Solutions, LLC Lexington,
KY. Samples were selected from horses between 1 to 4 years of
age. All samples were shipped to AHDC. Serum neutralization
(SN) antibodies were determined using an established assay. SN
titers  1:96 for ERV1&2 were considered positive.
Serum samples were evaluated in 1021 horses from regions of
the US and 451 (44%) were found to have neutralizing antibod-
ies  1:96 to ERV 1 and 164 (16%) were positive for ERV 2.
Seroprevalence of ERV 1 was highest in samples submitted from
Louisiana (49%), whereas samples from Kentucky had the lowest
seroprevalence rate (34%). Seroprevalence of ERV 2 ranged from
29% in AHDC sample submissions to 15% in Louisiana sam-
ples. Specific ages were available for 554 of the samples and sero-
prevalence for exposure to ERV 1 appeared to increase with age,
as positive titers to ERV 1 were found in yearlings (11/126 [9%]),
in 2 year olds (44/116 [38%]), 3 year olds (50/163 [31%]), and 4
year olds (52/149 [35%]).
ERV has high seroprevalence in several regions of the US. SN
antibodies to ERV 1 are more common than ERV 2 in the popu-
lations studied and seroprevalence appears to be age dependent.
ERV 1&2 infections and their relationship to concurrent respira-
tory disease and respiratory pathogens in horse populations war-
rant further investigation.
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Epistaxis is a severe manifestation of exercise-induced pulmo-
nary haemorrhage, seen in racing Thoroughbreds and other exer-
cising horses worldwide. The objectives of this study were to
report prevalence, incidence and recurrence of epistaxis, identify
risk factors and report effects of epistaxis upon performance.
Features of this study included the large data set, evaluation of
recurrence in jump and flat racing, all in a country where race
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